CAR-T Cell Therapy Biomarkers: Kyoto U Discovery | AcademicJobs
Kyoto University researchers identify 4MD biomarkers predicting CAR-T therapy success in blood cancers, advancing precision oncology in Japan.
No reviews yet. Be the first to rate Hidefumi!
Hidefumi Hiramatsu serves as a lecturer in the Department of Pediatrics at Kyoto University Hospital with concurrent affiliation in the Graduate School of Medicine at Kyoto University. He holds a Doctor of Philosophy degree in Medicine from Kyoto University. His research topics center on the analysis of genetic markers and minimal residual diseases of pediatric leukemia as well as investigating cytokine release syndrome and relapse following CAR-T cell therapy. Research interests include microRNA, pediatric leukemia, CAR-T cell therapy, minimal residual disease, hematopoietic stem cells, pediatric hematology, and pediatric oncology. Research areas fall under life sciences with emphasis on hematology and oncology as well as fetal medicine and pediatrics with a focus on oncology. He maintains professional memberships in the Japanese Cancer Association, the Japanese Society of Pediatric Hematology/Oncology, the Japan Pediatric Society, the American Society of Hematology, the Japanese Society for Hematopoietic Cell Transplantation, and the Japanese Society of Hematology. Hiramatsu has contributed extensively to the academic literature through numerous publications addressing pediatric blood cancers, CAR-T therapies, genetic analyses in leukemia, and related clinical topics in pediatric hematology and oncology.
Kyoto University researchers identify 4MD biomarkers predicting CAR-T therapy success in blood cancers, advancing precision oncology in Japan.